贵州百灵公告，公司实际控制人姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，被中 国证监会立案。本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关， 不会对上市公司及子公司生产经营活动产生影响。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 转自：证券时报 人民财讯12月3日电，贵州百灵(002424)12月3日公告，公司实控人姜伟近日收到证监会下发的立案告知 书。按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，证监会决定对其 进行立案。此次立案系对公司实控人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对公 司及子公司生产经营活动产生影响。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇12月3日丨贵州百灵（维权）(002424.SZ)公布，收到公司实际控制人姜伟先生的通知，其于近日 收到中国证券监督管理委员会（简称"中国证监会"）下发的《立案告知书》。按照该告知书，姜伟先生 因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》《中华人 民共和国行政处罚法》等法律法规，中国证监会决定对其进行立案。本次立案系对公司实际控制人姜伟 先生个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生影 响。 ...

格隆汇12月3日丨贵州百灵(002424.SZ)公布，收到公司实际控制人姜伟先生的通知，其于近日收到中国 证券监督管理委员会（简称"中国证监会"）下发的《立案告知书》。按照该告知书，姜伟先生因涉嫌内 幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》《中华人民共和国 行政处罚法》等法律法规，中国证监会决定对其进行立案。本次立案系对公司实际控制人姜伟先生个人 的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生影响。 ...

Core Viewpoint - The transformation of a "white knight" into a "barbarian" in the capital market is rare, exemplified by the recent legal dispute between Huachuang Securities and Guizhou Bailing, which began as a rescue cooperation but ended in court [2] Group 1: Background of Guizhou Bailing - Guizhou Bailing, established in 1999, became the "first stock of Miao medicine" in 2010, experiencing significant growth in both scale and performance, which elevated its controlling shareholder, Jiang Wei, to the status of a billionaire in Guizhou [3] - Jiang Wei actively invested in local ecological agriculture, cultural tourism, and government-recommended projects despite knowing these investments were unlikely to be profitable in the short term [4] Group 2: Financial Struggles and Rescue Agreement - Due to a downturn in the domestic capital market, Jiang Wei faced increasing pressure from stock pledges, having paid approximately 1.2 billion yuan in interest from 2011 to 2018 [5] - In December 2018, Guizhou Bailing signed a strategic cooperation agreement with Huachuang Securities, which provided 1.4 billion yuan in funding in exchange for an 11.54% equity stake and additional stock pledge loans [6] Group 3: Escalation of Dispute - Initially, Huachuang Securities promised not to seek control over Guizhou Bailing, but by early 2021, it had effectively taken over key financial roles within the company [8][10] - After the rescue plans' deadlines in 2022 and 2024, Huachuang Securities did not reduce its stock holdings as agreed, despite Guizhou Bailing's stock price reaching 11.97 yuan per share, significantly above Huachuang's cost [12] Group 4: Allegations of Malpractice - Huachuang Securities allegedly obstructed Guizhou Bailing from attracting strategic investors and engaged in actions that led to the failure of several cooperative projects [13] - From May 2020, Huachuang Securities conducted short-selling activities that coincided with significant stock price declines, raising suspicions of a strategy to acquire control at a lower cost [14][15] Group 5: Implications for the Capital Market - The dispute between Guizhou Bailing and Huachuang Securities serves as a typical case of conflict arising from rescue cooperation, highlighting the need for clearer regulations and enhanced supervision in the capital market to protect investor confidence [16]

Core Viewpoint - The originally positive rescue "marriage" between Guizhou Bai Ling and Huachuang Securities has turned into a bitter legal dispute, highlighting the complexities and risks associated with capital rescue efforts in distressed companies [1][2]. Group 1: Background of the Incident - In 2019, Guizhou Bai Ling's major shareholder Jiang Wei accepted a rescue plan from Huachuang Securities amid high pledge ratios, leading to a conflict over the terms of the agreement [1][5]. - Huachuang Securities provided 1.4 billion yuan in funding through share transfers, acquiring an 11.54% stake in Guizhou Bai Ling, and also extended 361 million yuan in stock pledge loans [5][6]. Group 2: Legal Proceedings - After multiple failed negotiations, Huachuang Securities filed a lawsuit against Jiang Wei and his associates, claiming a total of 1.4 billion yuan in principal and related fees [2]. - Jiang Wei counter-sued, demanding Huachuang Securities to fulfill its obligations and compensate for stock price losses due to alleged malicious actions [2]. Group 3: Control and Governance Issues - Huachuang Securities initially waived voting rights associated with its shares but later sought to regain these rights, indicating a shift in its approach to governance [6][7]. - A workgroup from Huachuang Securities took control of key management positions within Guizhou Bai Ling, raising concerns about its intentions to gain actual control over the company [7][8]. Group 4: Financial Performance and Stock Movements - During the rescue period, Guizhou Bai Ling's stock price peaked at 11.97 yuan per share, significantly above Huachuang Securities' acquisition cost, yet the latter did not sell its shares [10]. - Allegations arose that Huachuang Securities obstructed Guizhou Bai Ling's efforts to attract strategic investors, which could have facilitated the company's recovery [13][14]. Group 5: Regulatory and Compliance Aspects - Regulatory bodies have stated that Huachuang Securities has not been found to actively seek control over Guizhou Bai Ling, despite the ongoing disputes [8][16]. - The actions of Huachuang Securities during the rescue period have been scrutinized for compliance with regulations that prohibit seeking control and require clear exit strategies [6][10].

贵州百灵今年以来股价涨47.27%，近5个交易日跌8.25%，近20日跌2.74%，近60日跌9.86%。 分红方面，贵州百灵A股上市后累计派现14.47亿元。近三年，累计派现0.00元。 11月21日，贵州百灵（维权）盘中下跌2.07%，截至10:09，报5.67元/股，成交4205.22万元，换手率 0.61%，总市值79.24亿元。 资金流向方面，主力资金净流出500.95万元，特大单买入0.00元，占比0.00%，卖出367.11万元，占比 8.73%；大单买入746.30万元，占比17.75%，卖出880.14万元，占比20.93%。 资料显示，贵州百灵企业集团制药股份有限公司位于贵州省安顺市经济技术开发区西航路212号，成立 日期1999年3月25日，上市日期2010年6月3日，公司主营业务涉及以苗药为主的中成药的生产、销售。 主营业务收入构成为：中成药86.97%，西药8.44%，医疗服务2.27%，其他1.91%，中药材0.42%。 贵州百灵所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：抗流感、低价、民营医院、 中药、肝炎治疗等。 截至11月10日，贵州百灵股东户数8.58万，较 ...

Core Viewpoint - Guizhou BaiLing's stock price has experienced a decline recently, despite a significant increase of 52.73% year-to-date, indicating potential volatility in the market [2]. Group 1: Stock Performance - As of November 18, Guizhou BaiLing's stock price was 5.88 CNY per share, with a market capitalization of 8.218 billion CNY [1]. - The stock has seen a decline of 2.16% in the last five trading days, 2.00% in the last 20 days, and 2.97% in the last 60 days [2]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on August 5, where it recorded a net buy of -23.773 million CNY [2]. Group 2: Financial Performance - For the period from January to September 2025, Guizhou BaiLing reported revenue of 2.102 billion CNY, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 56.8144 million CNY, down 35.60% year-on-year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 1.447 billion CNY since its A-share listing [3]. Group 3: Shareholder Information - As of November 10, the number of shareholders for Guizhou BaiLing was 85,800, a decrease of 10.86% from the previous period, with an average of 14,132 circulating shares per person, an increase of 12.19% [2]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 14.0733 million shares as a new investor [3].

Core Viewpoint - Guizhou Bailing's stock price has shown significant growth this year, with a year-to-date increase of 61.82%, despite a decline in revenue and net profit for the first nine months of 2025 [1][2]. Group 1: Stock Performance - As of November 14, Guizhou Bailing's stock price rose by 2.13% to 6.23 CNY per share, with a trading volume of 1.07 billion CNY and a turnover rate of 1.43%, resulting in a total market capitalization of 8.707 billion CNY [1]. - The stock has experienced a net inflow of 2.1773 million CNY from main funds, with significant buying activity from large orders totaling 19.0999 million CNY, while selling from large orders reached 21.4768 million CNY [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on August 5, where it recorded a net buy of -23.773 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Guizhou Bailing reported operating revenue of 2.102 billion CNY, a decrease of 24.28% year-on-year, and a net profit attributable to shareholders of 56.8144 million CNY, down 35.60% year-on-year [2]. - The company has not distributed any dividends in the past three years, with a total payout of 1.447 billion CNY since its A-share listing [3]. Group 3: Shareholder Information - As of October 20, 2025, Guizhou Bailing had 96,300 shareholders, an increase of 15.19% from the previous period, with an average of 12,597 circulating shares per shareholder, a decrease of 13.19% [2]. - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 14.0733 million shares as a new shareholder [3].

Core Insights - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. has completed a B++ round of financing, with the amount undisclosed, and the investment firm involved is Guosheng Capital [1][2]. Financing Details - The B++ round financing was announced on November 9, 2025, with Guosheng Capital as the investor [2]. - Previous financing rounds include: - B+ round on August 4, 2025, with nearly 400 million RMB raised [2]. - B round on November 23, 2023, with undisclosed amounts [2]. - A+ round on October 14, 2022, with undisclosed amounts [2]. - A round on December 6, 2021, raising 107 million RMB [2]. - Angel round on January 19, 2021, with undisclosed amounts [2]. Company Focus - Zeling Biopharmaceutical specializes in the research and development of first-in-class and best-in-class innovative drugs, focusing on unmet clinical needs in areas such as malignant tumors, inflammation, and autoimmune diseases [1][2]. - The company is led by Professor Chen Lijuan from the State Key Laboratory of Biotherapy at West China Hospital of Sichuan University and collaborates with Guizhou BaiLing, a listed company, leveraging multidisciplinary research advantages [2].